Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Atriance Nelarabine Cancelled
Atripla Efavirenz, emtricitabine, tenofovir disoproxil fumarate HIV List with clinical criteria and/or conditions Complete
Aubagio Teriflunomide Multiple sclerosis, relapsing-remitting Do not list at the submitted price Complete
Avastin Bevacizumab Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Cervical Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Platinum Resistant Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Withdrawn
Avastin (with capecitabine) Bevacizumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete
Awiqli insulin icodec Diabetes mellitus, type 2 Reimburse with clinical criteria and/or conditions Complete